EMCURE

net profit jumped 48% YoY to ₹231 crore in Q3FY26, aided by strong international performance, better operating leverage and lower exceptional expenses. Revenue rose 20.4% to ₹2,363 crore, with overseas sales up 24.5%. CEO Satish Mehta cited a differentiated global pipeline and new launches, including biological injectable semaglutide Poviztra.